The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
Neuraminidase inhibitor (NAI) antiviral medications should be brought to bear early and often to stave off severe and fatal flu infections due to a vaccine mismatch this season, the CDC recommends.1
“The CDC recommends antiviral medications for treatment of influenza as an important adjunct to annual influenza vaccination,” the agency stated in its health advisory. “Treatment with neuraminidase inhibitors has been shown to have clinical and public health benefit in reducing illness and severe outcomes of influenza based on evidence from randomized controlled trials, meta-analyses of randomized controlled trials, and observational studies during past influenza seasons and during the 2009 H1N1 pandemic.… All hospitalized, severely ill, and high-risk patients with suspected or confirmed influenza should be treated with antivirals.”
Some of the key CDC recommendations are summarized as follows.
Any patient with suspected or confirmed influenza in the following categories should be treated as soon as possible with a neuraminidase inhibitor:
Financial Disclosure: Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, Peer Reviewer Patrick Joseph, MD, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.
Please update your cookie consent to make our free e-newsletters available to you by opting into marketing content.
If you are using an ad-blocker, you may also be unable to access our free content, you would need to enable scripts from marketo.com